Trials And tribulations Of Being Director Of The NIH

The past few months have been difficult ones for the National Institutes of Health and its director, James B. Wyngaarden. A series of public controversies has rocked the institution, tarnishing what many regard as the crown jewel of the federal scientific establishment. The Department of Health and Human Services, which oversees NIH, removed Edwin Becker as head of NIH’S Office of Research Services for “inefficiency and mismanagement,” despite strong opposition from Wyngaard

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

The past few months have been difficult ones for the National Institutes of Health and its director, James B. Wyngaarden. A series of public controversies has rocked the institution, tarnishing what many regard as the crown jewel of the federal scientific establishment. The Department of Health and Human Services, which oversees NIH, removed Edwin Becker as head of NIH’S Office of Research Services for “inefficiency and mismanagement,” despite strong opposition from Wyngaarden and his top staff The Office of Management and Budget insisted that NIH reduce the proportion of the more than 3,000 intramural managers and scientific staff on NIH’S Bethesda campus who receive outstanding performance citations— and the salary raises that accompany them—and reclassify downward some staffers so cited. And House subcommittees held two contentious hearings on fraud in biomedical science and NIH’S role in controlling it.

The 63-year-old Wyngaarden became NIH director in 1982, after establishing an enviable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies